


MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p style="text-align: center;">Licensee</p> <p>1. Teton Nuclear Medicine Service, LLC</p> <p>2. 2001 South Woodruff Avenue Suite 20 Idaho Falls, ID 83404-6370</p>		<p>In accordance with application dated May 23, 2022,</p>	<p>4. Expiration Date: October 31, 2037</p>
		<p>3. License No.: 11-27404-01 is renewed in its entirety to read as follows:</p>	<p>5. Docket No.: 030-32428 Reference No.:</p>
<p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material permitted by 10 CFR 35.100</p> <p>B. Any byproduct material permitted by 10 CFR 35.200</p> <p>C. Iodine-131 permitted by 10 CFR 35.300</p>	<p>7. Chemical and/or physical form</p> <p>A. Any</p> <p>B. Any</p> <p>C. Any</p>	<p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As Needed</p> <p>B. As Needed</p> <p>C. 65 millicuries total</p>	<p>9. Authorized use</p> <p>A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.</p> <p>B. For use in imaging and localization studies permitted by 10 CFR 35.200.</p> <p>C. Any use permitted by 10 CFR 35.300 for which the patient can be released under the provisions of 10 CFR 35.75.</p>



**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 11-27404-01

Docket or Reference No.:
030-32428

Amendment No. 8

CONDITIONS

10. Licensed material shall be used or stored at the licensee's facilities located at: 2001 South Woodruff Avenue, Suite 20, Idaho Falls, Idaho, 83404-6370.
11. The Radiation Safety Officer (RSO) for this license is Danny L. Davis, CNMT.
12. Licensed material shall only be used by, or under the supervision of:
- A. Individuals permitted to work as authorized users, in accordance with 10 CFR 35.13 and 10 CFR 35.14.
- B. The following individuals are authorized users for the material and medical uses as indicated:
- | <u>Authorized Users</u> | <u>Material and Use</u> |
|-----------------------------|--|
| Richard W. Bentley, M.D. | 35.100; 35.200; oral administration of sodium iodide I-131 |
| Michael C. Biddulph, M.D. | 35.100; 35.200; oral administration of sodium iodide I-131 |
| Dirk E. Bigler, D.O. | 35.100; 35.200; oral administration of sodium iodide I-131 |
| Douglas U. Blank, M.D. | 35.200 |
| Michael T. Callaghan, M.D. | Oral administration of sodium iodide I-131 |
| Marc Cardinal, M.D. | 35.100; 35.200 |
| John D. Chambers, Jr., M.D. | 35.200 |
| Neil Clinger, M.D. | Oral administration of sodium iodide I-131 |
| James P. Edlin, M.D. | 35.100; 35.200; oral administration of sodium iodide I-131 |
| Christopher O. Harker, M.D. | 35.100; 35.200; oral administration of sodium iodide I-131 |
| James B. Harris, M.D. | 35.100; 35.200; oral administration of sodium iodide I-131 |
| Robert Alan Harris, M.D. | Oral administration of sodium iodide I-131 |

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 11-27404-01

Docket or Reference No.:
030-32428

Amendment No. 8

Authorized Users

Justin A. Lamb, D.O.

Thomas J. Maley, M.D.

Calvin McAllister, M.D.

James Neely, M.D.

Richard M. Penney, M.D.

James F. Schmutz, M.D.

Steven D. Smith, M.D.

John J. Strobel, M.D.

Steven J. Todd, M.D.

David R. Warden III, M.D.

Alan Wray, M.D.

Material and Use

35.100; 35.200; oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries

35.200

Oral administration of sodium iodide I-131

35.100; 35.200; oral administration of sodium iodide I-131

Oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries

35.100; 35.200


35.100; 35.200; oral administration of sodium iodide I-131

35.100; 35.200; oral administration of sodium iodide I-131

Oral administration of sodium iodide I-131

35.100; 35.200

35.100; 35.200; oral administration of sodium iodide I-131



**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 11-27404-01

Docket or Reference No.:
030-32428

Amendment No. 8

13. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those statements, representations, and procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence impose on the licensee requirements that are more restrictive than or in addition to the regulations.

- A. Application dated May 23, 2022 (ML22143A956)
- B. Letter dated September 8, 2022 and email dated September 29, 2022 (ML22278B096)



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: October 6, 2022By: _____
Casey Alldredge
Region 4